Product Information
Contents: Cbl (C14) Blocking Peptide
Catalog Number: 66-P760
Sizes: 50 ug
Formulation: Each vial contains 100 μg of peptide in 0.5 ml PBS with 0.1% NaN3 and 100 μg BSA.
Storage Conditions: Store at 4°C. DO NOT FREEZE.
|
|
|
Questions? Please consult our answers to frequently asked questions at
http://www.ebioscience.com/faq.
Description
This is a peptide mapping to the carboxy terminal domain of human Cbl p120. The proto-oncogene c-Cbl was initially identified as the cellular homologue of v-Cbl oncogene that induces pre-B cell lymphomas and myeloid leukemias in mice (1&2). In more recent studies Cbl has been shown to be a negative regulator of tyrosine kinase signaling (2-4). The ubiquitin ligase activity of Cbl leads to the degradation of tyrosine kinases, thus attenuating the signal of receptors (3&4). Targets of Cbl include activated protein tyrosine kinases belonging to the Src and Syk/Zap-70 families (3). An additional mechanism to attenuate receptor signaling is thought to be achieved by Cbl?s interaction with downstream targets of tyrosine kinases, such as PI-3K and Vav (1&3).
Applications Reported
For research use only, not for diagnostic or therapeutic use. This blocking peptide has been reported for use in competition studies.
References
1. Liu YC, Altman A. 1998. Cbl: complex formation and functional implications. Cell Signal 10(6):377-385.
2. Miyake S, Lupher ML, Andoniou CE, Lill NL, Ota S, Douillard P, Rao N, Band H. 1997. The Cbl protooncogen product: from an enigmatic oncogene to center stage of signal transduction. Crit Rev Oncog 8(2-3):189-218.
3. Rao N, Dodge I, Band H. 2002. The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol 71(5):753-763.
4. Sanjay A, Horne WC, Baron R. 2001. The Cbl family: ubiquitin ligases regulating signaling by tyrosine kinase. Sci STKE 2001(110):PE40.
Related Products
Cat.
14-6760 Purified anti-mouse/human/rat Cbl polyclonal (clone Polyclonal)